Antihypertensive Mechanisms of Minocycline in Resistant Hypertension

Hypertension, Resistant to Conventional Therapy Clinical Trial

Official title:

Antihypertensive Mechanisms of Minocycline in Resistant Hypertension: Role of the Gut Microbiota-brain-immune Axis

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06246396
• Other study ID #: IRB202301939
• Secondary ID: 2R01HL132448-05A
• Status: Not yet recruiting
• Phase: Phase 4
• Start date: April 1, 2024
• Est. completion date: July 2028

Study information

• Verified date: January 2024
• Source: University of Florida
• Contact: Dana Leach, DNP
• Phone: 352-273-8933
• Email: leachdd[@]medicine.ufl.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to learn about the mechanisms by which minocycline effect blood pressure in individuals with treatment-resistant hypertension. The main questions it aims to answer are:

• To what extent does minocycline lower blood pressure and are these effects different across races?

• Are such blood pressure effects mediated through changes in gut microbiota, gut leakiness, systemic inflammation, neuroinflammation, or some combination of these?

Participants will be randomly assigned to treatment with minocycline or placebo, treated daily for 3 months, to evaluate these questions.

Description:

One hundred twenty patients (targeting 60 White patients and 60 Black or African American [AA] patients) with treatment-resistant hypertension will be enrolled. A total of 34 patients (17 from each treatment arm, with similar race distribution), who are participants in the main study, will also be enrolled in a substudy that includes neuroimaging. The study will last 3 months, and will include 3 visit time points (screening, randomization visit, 3-month follow-up visit).

Participants will be randomly assigned, in a 1:1 allocation, to minocycline 100 mg twice per day, or matching placebo, each provided by the study, and investigators will be blinded to treatment assignment.

At the baseline and 3-month follow-up visit, subjects will undergo:

• A comprehensive medical history and examination, including assessment of antihypertensive treatment history

• A series of behavioral activity questionnaires

• Blood tests (plasma renin activity, aldosterone, catecholamines, serum creatinine, lipid panel, hemoglobin a1c, as well as various biomarkers of immune and inflammatory activity, and gut leakiness markers)

• Urine/saliva tests for antihypertensive adherence

• Gut microbiota profiling via whole metagenomic sequencing of stool samples

• Blood pressure (BP) measurement, including unattended office BP and 24-hour ambulatory BP

Subjects enrolled in the neuroimaging substudy will also have PET/MR imaging performed at each visit. Neuroimaging activities will take place at Emory University in Atlanta, GA.

At the final visit (3-month follow-up), participants will also have blood tests to measure study drug concentration, as a measure of adherence to the assigned treatment.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 120
• Est. completion date: July 2028
• Est. primary completion date: July 2028
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• Age =18 years

• Self-identify as White or African American

• Uncontrolled TRH, defined as uncontrolled blood pressure (mean 24-hour ambulatory systolic BP =125 mm Hg or diastolic BP =80 mm Hg) while being adherent to a stable (no changes in =30 days prior) antihypertensive regimen of 3 or more drugs, including an adequately dosed thiazide or thiazide-like diuretic (hydrochlorothiazide =25 mg/day or equivalent)

• The participant agrees to have all study procedures performed

Exclusion Criteria:

• Known hypersensitivity or contraindication to minocycline or other tetracyclines

• Recent (=3 months prior), ongoing, or expected use of oral antibiotics

• Estimated glomerular filtration rate (eGFR) of <45mL/min/1.73m2, using the MDRD equation

• Known secondary hypertension

• History of antihypertensive crisis, defined as any in-patient hospitalizations for antihypertensive crisis/emergency within the past year

• History of orthostatic hypotension, defined as two or more episode(s) of orthostatic hypotension (reduction of SBP of >20 mm Hg or DBP of >10 mm Hg within 3 minutes of standing) in the past year

• History of myocardial infarction, unstable angina, syncope, or cerebrovascular accident in prior 6 months

• Evidence of alcoholism or drug abuse

• Severe comorbid conditions (i.e., neoplasms or HIV positive or AIDS)

• Ongoing or expected use of significant BP-interfering medications (excepting oral contraceptives)

• Current pregnancy or anticipated pregnancy during the study.

Related Conditions & MeSH terms

• Hypertension
• Hypertension, Resistant to Conventional Therapy

Intervention

Drug:
• Minocycline Hydrochloride
Minocycline Hydrochloride 100 mg twice daily
• Placebo
Placebo

Locations

Country	Name	City	State
United States	UF Health Cardiovascular Clinic	Gainesville	Florida

Sponsors (3)

Lead Sponsor	Collaborator
University of Florida	Emory University, National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	24-h systolic blood pressure	Change in mean 24-hour ambulatory systolic blood pressure	3 months
Primary	Gut microbiome	Change in butyrate-producing gene abundance	3 months
Primary	Gut inflammation and leakiness	Change in gut-homing inflammatory T-helper cells	3 months
Primary	Neuroinflammation	Change in [18F]FEPPA radiotracer uptake on PET/MR imaging	3 months
Secondary	Mucin-degrading gene abundance	Change in mucin-degrading gene abundance	3 months
Secondary	IgA+ coated plasma cells	Change in IgA+ coated plasma cells	3 months
Secondary	Gut leakiness markers	Change in gut leakiness markers, including lipocalin-2, intestinal fatty-acid binding protein (I-FABP), zonulin, and lipopolysaccharides (LPS)	3 months
Secondary	24-h diastolic blood pressure	Change in mean 24-hour diastolic blood pressure	3 months
Secondary	24-h heart rate	Change in mean 24-hour heart rate	3 months
Secondary	Adverse Events	Incidence of treatment-related adverse events	3 months